166 related articles for article (PubMed ID: 36054561)
41. Novel Selective Histone Deacetylase 6 (HDAC6) Inhibitors: A Patent Review (2016-2019).
He X; Li Z; Zhuo XT; Hui Z; Xie T; Ye XY
Recent Pat Anticancer Drug Discov; 2020; 15(1):32-48. PubMed ID: 32065106
[TBL] [Abstract][Full Text] [Related]
42. A novel class of anthraquinone-based HDAC6 inhibitors.
Song Y; Lim J; Seo YH
Eur J Med Chem; 2019 Feb; 164():263-272. PubMed ID: 30597327
[TBL] [Abstract][Full Text] [Related]
43. Design, Synthesis and Biological Evaluation of a Phenyl Butyric Acid Derivative, N-(4-chlorophenyl)-4-phenylbutanamide: A HDAC6 Inhibitor with Anti-proliferative Activity on Cervix Cancer and Leukemia Cells.
Rodríguez-Fonseca RA; Sixto-López Y; Fragoso-Vázquez MJ; Flores-Mejía R; Cabrera-Pérez LC; Vázquez-Moctezuma I; Rosales-Hernández MC; Bello M; Martínez-Archundia M; Trujillo-Ferrara JG; Becerra-Martínez E; Correa-Basurto J
Anticancer Agents Med Chem; 2017; 17(10):1441-1454. PubMed ID: 28044941
[TBL] [Abstract][Full Text] [Related]
44. Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.
Wagner FF; Olson DE; Gale JP; Kaya T; Weïwer M; Aidoud N; Thomas M; Davoine EL; Lemercier BC; Zhang YL; Holson EB
J Med Chem; 2013 Feb; 56(4):1772-6. PubMed ID: 23368884
[TBL] [Abstract][Full Text] [Related]
45. A Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective Inhibitors.
Goracci L; Deschamps N; Randazzo GM; Petit C; Dos Santos Passos C; Carrupt PA; Simões-Pires C; Nurisso A
Sci Rep; 2016 Jul; 6():29086. PubMed ID: 27404291
[TBL] [Abstract][Full Text] [Related]
46. Development of selective HDAC6 inhibitors with in vitro and in vivo anti-multiple myeloma activity.
Li S; Zhao C; Zhang G; Xu Q; Liu Q; Zhao W; James Chou C; Zhang Y
Bioorg Chem; 2021 Nov; 116():105278. PubMed ID: 34474303
[TBL] [Abstract][Full Text] [Related]
47. Structure, Functions and Selective Inhibitors of HDAC6.
Liang T; Fang H
Curr Top Med Chem; 2018; 18(28):2429-2447. PubMed ID: 30499393
[TBL] [Abstract][Full Text] [Related]
48. Novel quinolone-based potent and selective HDAC6 inhibitors: Synthesis, molecular modeling studies and biological investigation.
Relitti N; Saraswati AP; Chemi G; Brindisi M; Brogi S; Herp D; Schmidtkunz K; Saccoccia F; Ruberti G; Ulivieri C; Vanni F; Sarno F; Altucci L; Lamponi S; Jung M; Gemma S; Butini S; Campiani G
Eur J Med Chem; 2021 Feb; 212():112998. PubMed ID: 33199154
[TBL] [Abstract][Full Text] [Related]
49. Exploring the inhibitory activity of valproic acid against the HDAC family using an MMGBSA approach.
Sixto-López Y; Bello M; Correa-Basurto J
J Comput Aided Mol Des; 2020 Aug; 34(8):857-878. PubMed ID: 32180123
[TBL] [Abstract][Full Text] [Related]
50. Structural determinants of affinity and selectivity in the binding of inhibitors to histone deacetylase 6.
Osko JD; Christianson DW
Bioorg Med Chem Lett; 2020 Apr; 30(8):127023. PubMed ID: 32067866
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis and biological evaluation of 3, 4-disubstituted-imidazolidine-2, 5-dione derivatives as HDAC6 selective inhibitors.
Liang T; Xue J; Yao Z; Ye Y; Yang X; Hou X; Fang H
Eur J Med Chem; 2021 Oct; 221():113526. PubMed ID: 33992929
[TBL] [Abstract][Full Text] [Related]
52. Difluoromethyl-1,3,4-oxadiazoles are slow-binding substrate analog inhibitors of histone deacetylase 6 with unprecedented isotype selectivity.
Cellupica E; Caprini G; Cordella P; Cukier C; Fossati G; Marchini M; Rocchio I; Sandrone G; Vanoni MA; Vergani B; Źrubek K; Stevenazzi A; Steinkühler C
J Biol Chem; 2023 Jan; 299(1):102800. PubMed ID: 36528061
[TBL] [Abstract][Full Text] [Related]
53. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated.
Géraldy M; Morgen M; Sehr P; Steimbach RR; Moi D; Ridinger J; Oehme I; Witt O; Malz M; Nogueira MS; Koch O; Gunkel N; Miller AK
J Med Chem; 2019 May; 62(9):4426-4443. PubMed ID: 30964290
[TBL] [Abstract][Full Text] [Related]
54. Discovery of novel potential selective HDAC8 inhibitors by combine ligand-based, structure-based virtual screening and in-vitro biological evaluation.
Debnath S; Debnath T; Bhaumik S; Majumdar S; Kalle AM; Aparna V
Sci Rep; 2019 Nov; 9(1):17174. PubMed ID: 31748509
[TBL] [Abstract][Full Text] [Related]
55. Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).
Feng T; Wang H; Su H; Lu H; Yu L; Zhang X; Sun H; You Q
Bioorg Med Chem; 2013 Sep; 21(17):5339-54. PubMed ID: 23820574
[TBL] [Abstract][Full Text] [Related]
56. A Computational Approach to Investigate the HDAC6 and HDAC10 Binding Propensity of Psidium guajava-derived Compounds as Potential Anticancer Agents.
Adewole KE; Ishola AA
Curr Drug Discov Technol; 2021; 18(3):423-436. PubMed ID: 32357815
[TBL] [Abstract][Full Text] [Related]
57. Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
Jiang BE; Hu J; Liu H; Liu Z; Wen Y; Liu M; Zhang HK; Pang X; Yu LF
Eur J Med Chem; 2022 Jan; 227():113893. PubMed ID: 34656899
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of WO2017018805: 1,3,4-oxadiazole sulfamide derivatives as selective HDAC6 inhibitors.
Liang YY; Zhang CM; Liu ZP
Expert Opin Ther Pat; 2018 Aug; 28(8):647-651. PubMed ID: 30073889
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and biological evaluation of brain penetrant benzazepine-based histone deacetylase 6 inhibitors for alleviating stroke-induced brain infarction.
Guo Z; Zhang Z; Zhang Y; Wang G; Huang Z; Zhang Q; Li J
Eur J Med Chem; 2021 Jun; 218():113383. PubMed ID: 33799069
[TBL] [Abstract][Full Text] [Related]
60. Discovery and SAR analysis of 5-chloro-4-((substituted phenyl)amino)pyrimidine bearing histone deacetylase inhibitors.
Zhang L; Chen Y; Li F; Zhang L; Feng J; Zhang L
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1918-1927. PubMed ID: 35833370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
